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abstract
PURPOSE To develop an evidence-based clinical practice guideline to assist in clinical decision making for
patients with resected biliary tract cancer.
METHODS ASCO convened an Expert Panel to conduct a systematic review of the literature on adjuvant therapy
for resected biliary tract cancer and provide recommended care options for this patient population.
RESULTS Three phase III randomized controlled trials, one phase II trial, and 16 retrospective studies met the
inclusion criteria.
RECOMMENDATIONS Based on evidence from a phase III randomized controlled trial, patients with resected
biliary tract cancer should be offered adjuvant capecitabine chemotherapy for a duration of 6 months. The
dosing used in this trial is described in the qualifying statements, while it should be noted that the dose of
capecitabine may also be determined by institutional and regional practices. Patients with extrahepatic
cholangiocarcinoma or gallbladder cancer and a microscopically positive surgical resection margin (R1 re-
section) may be offered chemoradiation therapy. A shared decision-making approach is recommended,
considering the risk of harm and potential for beneﬁt associated with radiation therapy for patients with ex-
trahepatic cholangiocarcinoma or gallbladder cancer. Additional information is available at www.asco.org/
gastrointestinal-cancer-guidelines.
J Clin Oncol 37:1015-1027. © 2019 by American Society of Clinical Oncology
INTRODUCTION
Biliary tract cancers include cancer of the intrahepatic
bile ducts, perihilar and distal extrahepatic bile ducts,
and the gallbladder. There were an estimated 12,190
new diagnoses and 3,790 deaths from gallbladder and
extrahepatic bile duct cancer in the United States in
2018.1 Five-year relative survival rates range from 2%
to 15% and from 2% to 30% for intrahepatic and
extrahepatic cholangiocarcinoma, respectively,2 while
the 5-year relative survival rate for gallbladder cancer
ranges from 2% to 70%, depending on stage.3 Hilar
tumors account for approximately 60% to 70% of
cholangiocarcinomas.4 Gallbladder cancer is the most
common site of biliary tract cancer and is also asso-
ciated with shorter time to recurrence and survival time
after recurrence than hilar cholangiocarcinoma.5 Bil-
iary tract cancers are relatively rare in the Western
world; however, higher incidence clusters have been
found in some areas of Asia and the Andes.6
Biliary tract cancers usually present at an advanced
stage, and only approximately 20% of tumors are
considered resectable.7 Surgery is the primary curative
treatment option for early-stage biliary tract cancer;
however, due to the high rates of recurrence with
resection alone, there remains a need for effective
adjuvant therapy to improve rates of relapse-free
survival (RFS) and overall survival (OS), while main-
taining health-related quality of life.8
Studies of adjuvant treatment options have historically
been small, retrospective, and nonrandomized and in-
clude a mix of patients with gallbladder and other biliary
tract tumors.9 In addition, recommendations from clinical
practice guidelines have largely been consensus
based.5,10,11 Recently, results from prospective trials
of adjuvant therapy for biliary tract cancers have been
published, including randomized controlled compari-
sons of chemotherapy options compared with observa-
tion and a prospective single-arm trial of chemoradiation.
The purpose of this guideline development project is to
review this newer evidence and provide evidence-based
recommendations for adjuvant therapy for patients with
resected biliary tract cancer, as well as to consider
recommendations for patients who are at higher risk
for microscopically positive resection margins.
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GUIDELINE QUESTION
This clinical practice guideline addresses the following clinical
question: Is adjuvant therapy, including ﬂuoropyrimidine-
based or gemcitabine-based chemotherapy and/or radiation
therapy, recommended for patients with resected biliary
tract cancer?
METHODS
Guideline Development Process
This systematic review–based guideline was developed by
a multidisciplinary Expert Panel, which included members
with expertise in surgical oncology, medical oncology, ra-
diation oncology, practice guideline implementation, and
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Guideline Question
Is adjuvant therapy, including ﬂuoropyrimidine-based or gemcitabine-based chemotherapy and/or radiation
therapy, recommended for patients with resected biliary tract cancer?
Target Population
Patients with resected biliary tract cancer.
Target Audience
Oncologists (medical, radiation, and surgical) and other health care professionals who treat patients with biliary tract
cancer, patients, and caregivers.
Methods
An Expert Panel was convened to develop clinical practice guideline recommendations based on a systematic
review of the medical literature.
Recommendations
Recommendation 1. Patients with resected biliary tract cancer should be offered adjuvant capecitabine che-
motherapy for a duration of 6 months (Type: Evidence based; Beneﬁts outweigh harms; Evidence quality: In-
termediate; Strength of recommendation: Moderate).
Qualifying statements.
• In the BILCAP (Adjuvant Capecitabine for Biliary Tract Cancer) phase III randomized controlled trial,
capecitabine was delivered at a dose of 1,250 mg/m2 twice a day on treatment days 1 to 14 of a 3-week cycle
for 24 weeks (eight cycles).12
• The Expert Panel agrees that the recommended dose of capecitabine may be determined by institutional and
regional practices.
Recommendation 2. Patients with extrahepatic cholangiocarcinoma or gallbladder cancer and a microscopically
positive surgical margin resection (R1 resection) may be offered chemoradiotherapy (Type: Evidence and Con-
sensus based; Beneﬁts outweigh harms; Evidence quality: Low; Strength of recommendation: Moderate).
Qualifying statements.
• A shared decision-making approach is recommended, considering the risk of potential harm and potential for
beneﬁt associated with radiation therapy for patients with extrahepatic cholangiocarcinoma or gallbladder
cancer.
• The Expert Panel notes that in the SWOG0809 prospective single-arm trial of chemoradiotherapy,13 radiation
was delivered at a dose of 45 Gy to regional lymphatics and 54 to 59.4 Gy to the tumor bed. However, at this
time, the evidence base is not sufﬁciently well developed to make a recommendation for optimal dosing of
radiation therapy in the context of chemoradiation therapy.
Additional Resources
More information, including a Data Supplement with additional evidence tables, slide sets, and clinical tools and
resources, is available at www.asco.org/gastrointestinal-cancer-guidelines. The Methodology Manual (available at
www.asco.org/guideline-methodology) provides additional information about the methods used to develop this
guideline. Patient information is available at www.cancer.net.
ASCO believes that cancer clinical trials are vital to inform medical decisions and improve cancer care, and that all
patients should have the opportunity to participate.
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health research methodology, as well as a member rep-
resenting the patient perspective. The Expert Panel (Ap-
pendix Table A1, online only) met via teleconference and/or
webinar and corresponded through e-mail. Based on
consideration of the evidence, the authors were asked to
contribute to the development of the guideline, provide
critical review, and ﬁnalize the guideline recommendations.
The guideline recommendations were sent for an open
comment period of 2 weeks, allowing the public to review
and comment on the recommendations after submitting a
conﬁdentiality agreement. These comments were taken
into consideration while ﬁnalizing the recommendations.
Members of the Expert Panel were responsible for reviewing
and approving the penultimate version of the guideline,
which was then submitted to Journal of Clinical Oncology
for editorial review and consideration for publication. All
ASCO guidelines are ultimately reviewed and approved by
the Expert Panel and the ASCO Clinical Practice Guidelines
Committee before publication. All funding for the admin-
istration of the project was provided by ASCO.
PubMed was systematically searched from January 2008 to
June 30, 2018, for full-text publications of randomized
controlled trials, prospective controlled studies, or single-
arm trials. Details of the search strategy are provided in the
Data Supplement. Articles were selected for inclusion if
they were studies of adjuvant chemotherapy and/or ra-
diotherapy for patients with resected biliary tract cancer. A
search of recent abstracts (2017 to 2018) from the ASCO
Annual Meeting and the ASCO Gastrointestinal Cancers
Symposium was also conducted for the article types
mentioned previously.
Resection margins are classiﬁed as R0 (negative margins),
R1 (positive microscopic margins), or R2 (positive mac-
roscopic margins).14 Margin status is highly correlated with
local recurrence and survival.11 The Expert Panel recog-
nized that the subset of patients with hilar extrahepatic
cholangiocarcinoma have a higher likelihood of micro-
scopically positive (R1) resection margins than patients
with other disease sites due to the central location of the
tumor,15 and the panel chose to extend the search in this
patient population to include retrospective studies from
January 1, 2004, to June 30, 2018. Abstracts were not
considered for potential inclusion in this extended search.
Reference lists of systematic reviews found in the PubMed
search were used as a source of potential articles for
inclusion. Outcomes of interest included OS, RFS, ad-
verse events, and quality of life. Articles were excluded
from the systematic review if they were editorials, com-
mentaries, letters, news articles, case reports, narra-
tive reviews, or if they were published in a non-English
language.
The guideline recommendations were crafted, in part,
using the Guidelines Into Decision Support methodology
and accompanying BRIDGE-Wiz software (Yale University,
NewHaven, CT).16 In addition, a guideline implementability
review was conducted. Based on the implementability
review, revisions were made to the draft to clarify recom-
mended actions for clinical practice. Ratings for the type
and strength of recommendation, evidence, and potential
bias are provided with each recommendation.
Study Quality Assessment
Risk of bias in the phase III randomized controlled trials was
assessed using the Cochrane Risk of Bias Tool.17 Additional
quality domains, including imprecision, inconsistency, in-
directness, and potential for publication bias, were also
assessed.18 A risk-of-bias assessment of the SWOG0809
trial was conducted using the Risk of Bias in Non-
observational Studies of Intervention tool.19 The retro-
spective observational studies included in this review were
rated using guidance contained within the Cochrane
Handbook for Systematic Reviews of Interventions (Section
12.2.1),18 which generally rates observational studies as
low quality due to issues of residual confounding and se-
lection bias inherent to nonrandomized study designs.
However, observational studies may be rated as higher
quality if the effect size is large and there is no obvious bias
explaining those effects, when there is an apparent dose-
response gradient, or when residual confounding after
adjusted analysis would be expected to lessen the likeli-
hood of a signiﬁcant result.18
Further information about the methods used to develop this
guideline is available in the Methodology Manual at www.
asco.org/guideline-methodology, including an overview
(eg, panel composition, development process, and revision
dates), literature search and data extraction, the recom-
mendation development process (Guidelines Into Decision
Support and BRIDGE-Wiz), and quality assessment.
The ASCO Expert Panel and guidelines staff will work with
co-chairs to keep abreast of any substantive updates to the
guideline. ASCO uses a signals approach to updating,
which is designed to identify only new, potentially practice-
changing data—signals—that might translate into revised
practice recommendations.20 The approach relies on tar-
geted routine literature searching and the expertise of
ASCO Expert Panel members to help identify potential
signals. The Methodology Manual (available at www.asco.
org/guideline-methodology) provides additional information
about the methods used to develop this guideline. This is
the most recent information as of the publication date.
Guideline Disclaimer
The Clinical Practice Guidelines and other guidance
published herein are provided by the American Society of
Clinical Oncology, Inc. (ASCO) to assist providers in clinical
decision making. The information herein should not be
relied upon as being complete or accurate, nor should it be
considered as inclusive of all proper treatments or methods
of care or as a statement of the standard of care. With the
rapid development of scientiﬁc knowledge, new evidence
may emerge between the time information is developed
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and when it is published or read. The information is not
continually updated and may not reﬂect the most recent
evidence. The information addresses only the topics spe-
ciﬁcally identiﬁed therein and is not applicable to other
interventions, diseases, or stages of diseases. This information
does not mandate any particular course of medical care.
Further, the information is not intended to substitute for the
independent professional judgment of the treating provider,
as the information does not account for individual variation
among patients. Recommendations reﬂect high,moderate, or
low conﬁdence that the recommendation reﬂects the net
effect of a given course of action. The use of words like
“must,” “must not,” “should,” and “should not” indicates that
a course of action is recommended or not recommended for
either most or many patients, but there is latitude for the
treating physician to select other courses of action in indi-
vidual cases. In all cases, the selected course of action should
be considered by the treating provider in the context of
treating the individual patient. Use of the information is vol-
untary. ASCOprovides this information on an “as is” basis and
makes no warranty, express or implied, regarding the in-
formation. ASCO speciﬁcally disclaims any warranties of
merchantability or ﬁtness for a particular use or purpose.
ASCO assumes no responsibility for any injury or damage to
persons or property arising out of or related to any use of this
information, or for any errors or omissions.
Guideline and Conﬂicts of Interest
The Expert Panel was assembled in accordance with
ASCO’s Conﬂict of Interest Policy Implementation for
Clinical Practice Guidelines (“Policy,” found at http://www.
asco.org/rwc). All members of the Expert Panel completed
ASCO’s disclosure form, which requires disclosure of ﬁ-
nancial and other interests, including relationships with
commercial entities that are reasonably likely to experience
direct regulatory or commercial impact as a result of pro-
mulgation of the guideline. Categories for disclosure in-
clude employment; leadership; stock or other ownership;
honoraria, consulting or advisory role; speaker’s bureau;
research funding; patents, royalties, other intellectual
property; expert testimony; travel, accommodations, ex-
penses; and other relationships. In accordance with the
Policy, the majority of the members of the Expert Panel did
not disclose any relationships constituting a conﬂict under
the Policy.
RESULTS
Summary of Results
Four prospective studies met the inclusion criteria for this
review, including three phase III randomized controlled
trials of chemotherapy compared with observation12,21,22
and a prospective single-arm trial of chemoradiation.13
Study characteristics, including chemotherapy dose and
schedule information, are listed in Table 1. RFS, median
and 5-year OS, pattern of relapse, quality of life, and
adverse events were extracted where reported and are
listed in Tables 2 to 4. Further description of each of these
prospective trials is included in Recommendations. In
addition, 16 retrospective studies that included data for
patients with hilar cholangiocarcinoma were included in the
evidence base. The characteristics and outcomes of these
studies are further described under Recommendation 2
and within Data Supplement Tables 1 to 4.
Quality Assessment of the Literature (Data Supplement
Tables 5 and 6)
Randomized controlled trials. The results across the three
trials of chemotherapy compared with observation and
surveillance included one positive12 and two negative
trials.21,22 All phase III trials were found to be at risk for bias
due to lack of blinding of study participants and personnel;
however, this risk would have been less serious for the
outcome of OS.12,21,22 Patient characteristics were well
balanced between study arms across trials. Results were
provided for the intent-to-treat population.12,21,22
The study by Ebata et al21 failed to accrue the planned
number of patients, which could have resulted in an un-
derpowered analysis. However, the authors of this study
note that this factor was unlikely to have affected the ﬁnal
results. The PRODIGE 12 trial had signiﬁcant imprecision
around the estimate for the primary outcome of RFS.22
Evidence quality (ie, certainty) for the comparisons of
gemcitabine plus oxaliplatin or gemcitabine alone versus
observation was judged to be low due to these limitations.
The survival outcomes for the comparison of capecitabine
versus observation (BILCAP [Adjuvant Capecitabine for
Biliary Tract Cancer])12 were rated as intermediate quality
as a result of the signiﬁcant magnitude of the OS effect in
the per-protocol and prespeciﬁed adjusted ITT analyses.
Nonrandomized studies. The remainder of the studies were
retrospective observational studies rated as low quality due
to issues of residual confounding and selection bias in-
herent to nonrandomized study designs.18 The phase II
SWOG0809 single-arm trial included patients with a higher
rate of R0 resections than expected based on historical
data.13 For the studies that included patients with hilar
cholangiocarcinoma,21,23-37 methodologic or quality issues
included inconsistency of intervention and included pop-
ulations across some studies, as well as smaller sample
sizes within the studies that were conducted at single in-
stitutions. Risk of bias due to confounding was reduced in
some studies by adjusting for prognostic factors or by
matching patients according to their likelihood of receiving
adjuvant therapy.
RECOMMENDATIONS
Clinical Question
Is adjuvant therapy, including ﬂuoropyrimidine-based or
gemcitabine-based chemotherapy and/or radiation therapy,
recommended for patients with resected biliary tract cancer?
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Recommendation 1
Patients with resected biliary tract cancer should be offered
adjuvant capecitabine chemotherapy for a duration of 6months
(Type: Evidence-based; Beneﬁts outweigh harms; Evidence
quality: Intermediate; Strength of recommendation: Moderate).
Qualifying statements.
• In the BILCAP phase III randomized controlled trial,
capecitabine was delivered at a dose of 1,250 mg/m2
twice a day on treatment days 1 to 14 of a 3-week cycle
for 24 weeks (eight cycles).12
• The Expert Panel agrees that the recommended dose
of capecitabinemay be determined by institutional and
regional practices.
Literature review and analysis. BILCAP (United Kingdom).
The BILCAP study12 included 447 patients with intrahepatic
cholangiocarcinoma (19%), hilar cholangiocarcinoma (29%),
muscle-invasive gallbladder cancer (18%), or chol-
angiocarcinoma of the lower common bile duct (35%). The
percentages of patients reported to have involved lymph
nodes in this trial in the treatment and control groups were
45% and 48%, respectively. The rate of R1 resection was
38% in both the treatment and control groups. The study
included patients with Eastern Cooperative Oncology Group
(ECOG) performance status (PS) of 0 to 2 who had un-
dergone R0 or R1 resections.
This study found a signiﬁcant difference in OS in a pre-
speciﬁed ITT analysis adjusted for nodal status, disease
grade, and sex (hazard ratio [HR], 0.71; 95% CI, 0.55 to
0.92; P , .01). A per-protocol analysis also found a sig-
niﬁcant difference in OS (HR, 0.75; 95% CI, 0.58 to 0.97;
P = .028) in favor of capecitabine versus observation, while
there was no signiﬁcant difference in unadjusted ITT OS
(HR, 0.81; 95% CI, 0.63 to 1.04; P = .097). RFS also
signiﬁcantly favored the experimental group in this study
(HR, 0.71; 95% CI, 0.54 to 0.92; P = .001; Table 2). There
were no signiﬁcant differences in quality of life, and the
most common adverse event in the capecitabine group was
palmar-plantar erythema (21%; Table 4).
PRODIGE 12 (France). The PRODIGE 12 study22 included
194 patients with intrahepatic (46%), perihilar (8%), or
distal (27%) cholangiocarcinoma or gallbladder adeno-
carcinoma (20%). The percentage of patients with involved
lymph nodes was 63% in the gemcitabine and oxaliplatin
group and 64% in the surveillance group. The R0 resection
rates in the treatment and control groups were 86% and
88%, respectively, while the remainder were R1 resections.
The ECOG PS for patients ranged from 0 to 2.
No signiﬁcant differences between the gemcitabine and
oxaliplatin and surveillance groups were found for the primary
outcomes in this study, including RFS (HR, 0.88; 95% CI,
0.62 to 1.25; P = .48) and global health-related quality-of-life
scores at 12 months (70.8 v 83.3, respectively; P = .18) and
24 months (75.0 v 83.3, respectively; P = .50).
Ebata et al (Japan). This study included patients with ex-
trahepatic cholangiocarcinoma (45% hilar, 55% distal) and
ECOG PS of 0 or 1. The percentages of patients reported to
have involved lymph nodes in the treatment and control
groups were 64% and 67%, respectively. The R0 resection
rates in the treatment and control groups were 91% and
87%, respectively, while the remainder were R1 resections.
There was no signiﬁcant difference in RFS (HR, 0.93; 95%
CI, 0.66 to 1.32; P = .693) or OS (HR, 1.01; 95% CI, 0.70 to
1.45; P = .964) in this study.
Clinical interpretation. Based on the signiﬁcant results of
the BILCAP trial, the Expert Panel recommends that
capecitabine for a period of 6 months should be offered as
adjuvant therapy to patients with resected biliary tract
cancer. No high-level evidence was found to warrant the
recommendation of radiation therapy alone for patients with
biliary tract cancer.
Recommendation 2
Patients with extrahepatic cholangiocarcinoma or gall-
bladder cancer and a microscopically positive surgical
margin resection (R1 resection) may be offered chemo-
radiation therapy (Type: Evidence and Consensus based;
Beneﬁts outweigh harms; Evidence quality: low; Strength of
recommendation: Moderate).
Qualifying statements.
• A shared decision-making approach is recommended,
considering the potential risk of harm and potential for
beneﬁt associated with radiation therapy for patients
with extrahepatic cholangiocarcinoma or gallbladder
cancer.
• The Expert Panel notes that in the SWOG0809 pro-
spective single-arm trial of chemoradiotherapy,13 ra-
diation was delivered at a dose of 45 Gy to regional
lymphatics and 54 to 59.4 Gy to the tumor bed.
However, at this time, the evidence base is not sufﬁ-
ciently well developed to make a recommendation for
optimal dosing of radiation therapy in the context of
chemoradiation therapy.
Literature review and analysis. Sixteen nonrandomized
studies provided data for outcomes of adjuvant therapy in
patients with hilar cholangiocarcinoma, combined hilar
and/or distal cholangiocarcinoma, and/or gallbladder
cancer (Data Supplement).21,23-37 Because this group of
studies was rated low quality, the Expert Panel largely relied
on informal consensus for the development of Recom-
mendation 2. Limited supportive evidence for this rec-
ommendation within the 16 studies includes the ﬁnding of a
signiﬁcant positive association between OS and adjuvant
external-beam radiotherapy in the R1/R2 subgroup, but not
in the R0 subgroup, in the single-institution study of pa-
tients with hilar cholangiocarcinoma by Cheng et al.25 In
addition, a signiﬁcant positive association between RFS
and OS and any adjuvant therapy was found in the
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multi-institution study of patients with hilar cholangiocarcinoma
by Krasnick et al,30 in which 40% of treated patients had an
R1 resection.
Because of the limited and inconsistent outcomes data
available for patients with hilar cholangiocarcinoma, the
Expert Panel also discussed the relevance of included
studies that provided data for other biliary tract subsites.
This included the SWOG0809 phase II study of chemo-
radiation (Table 1 provides dose and timing) that reported
outcomes for 79 patients with hilar cholangiocarcinoma
(48%), distal cholangiocarcinoma (16%), or gallbladder
cancer (32%).13 The authors of this study found a similar
rate of local recurrence and median OS in the R0 and R1
subgroups, where poorer outcomes in the R1 group would
have been expected based on historical data. They cau-
tiously attribute the efﬁcacy of adjuvant therapy in R1
patients in this study to the positive effect of treatment.13
Other supporting data for Recommendation 2 include a
meta-analysis by Horgan et al,8 which included 20 studies
from 1960 to 2010 and contained a similar evidence base
as this review. In an analysis by margin status, the authors
found a signiﬁcant beneﬁt of adjuvant therapy in patients
TABLE 2. Outcomes of Randomized Controlled Trials of Adjuvant Therapy for Resected Biliary Tract Carcinoma
Study and Year Interventions No. of Patients RFS OS
Pattern of First
Relapse (%)
Primrose et al,12 2017
ITT analysis Cap v Obs Cap, 223;
Obs, 224
Cap: median, 24.6
months (95% CI, 18.9
to 36.7 months)
Obs: median, 17.6
months (95% CI, 12.8
to 27.6 months)
HR, 0.76 (95% CI, 0.58
to 0.99; P = .039)
Cap: median, 51.1
months (95% CI, 34.6
to 59.1 months)
Obs: median, 36.4
months (95% CI, 29.7
to 44.5 months)
HR, 0.81 (95% CI, 0.63
to 1.04; P = .097)
Prespeciﬁed adjusted
(nodal status, grade,
sex) ITT analysis: HR,
0.71 (95% CI, 0.55 to
0.92; P , .01)
NR
Per-protocol analysis Cap v Obs Cap, 210;
Obs, 220
Cap: median, 25.9
months (95% CI, 19.8
to 46.3 months)
Obs: median, 17.6
months (95% CI, 12.0
to 23.8 months)
HR, 0.71 (95% CI, 0.54
to 0.92; P = .001)
Cap: median, 52.7
months (95% CI,
40.3 months to NR)
Obs: median, 36.1
months (95% CI,
29.6 to 44.2 months)
HR, 0.75 (95% CI,
0.58 to 0.97; P = .028)
NR
Edeline et al,22 2017 GEMOX v
surveillance
GEMOX, 95;
surveillance, 99
GEMOX: median, 30.4
months (95% CI, 15.4
to 43.0 months)
Surveillance: median,
18.5 months (95% CI,
12.6 to 38.2 months)
HR, 0.88 (95% CI, 0.62
to 1.25; P = .48)
GEMOX v surveillance:
24-month OS, 69% v
76%; 48-months OS,
51% v 52%; 72-month
OS, 51% v 48%
Metastatic recurrence:
GEMOX, 75%;
surveillance, 71%
Ebata et al,21 2018 Gem v Obs Gem, 117; Obs,
108
Gem: median, 36.0
months
Obs: median, 39.9
months
HR, 0.93 (95% CI, 0.66
to 1.32; P = .693)
Gem: median,
62.3 months
Obs, median,
63.8 months
HR, 1.01 (95% CI, 0.70
to 1.45; P = .964)
Liver: Gem, 24.8%; Obs,
24.8%
Local: Gem, 13.7%; Obs,
17.6%
Peritoneum: Gem,
12.0%; Obs, 17.6%
Abdominal lymph node:
Gem, 14.5%;
Obs, 12.0%
Lung: Gem, 5.1%;
Obs, 2.8%
Other: Gem, 6.8%;
Obs, 7.4%
Abbreviations: Cap, capecitabine; Gem, gemcitabine; GEMOX, gemcitabine and oxaliplatin; HR, hazard ratio; ITT, intent-to-treat; NR, not reported; Obs,
observation; OS, overall survival; RFS, relapse-free survival.
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with cholangiocarcinoma with R1 resections (odds ratio,
0.36; 95% CI, 0.14 to 0.92; P = .03). The authors also
found a beneﬁt of adjuvant radiation for all patients with
biliary tract cancer with R1 resection (odds ratio, 0.33; 95%
CI, 0.14 to 0.81; P , .01), whereas radiation therapy was
not shown to be effective in R0 patients.8
Based on these data and the demonstrated higher rate of R1
resection in patients with hilar cholangiocarcinoma due to
the location of the tumor, the Expert Panel agreed that
adjuvant chemoradiation therapy may be offered for patients
with hilar cholangiocarcinoma with R1 resections. Patients
with extrahepatic and gallbladder cholangiocarcinoma with
R1 resections are also included within Recommendation 2,
because the Expert Panel agreed that the effect of che-
moradiation would not be expected to differ by site and
because the evidence contributing to this judgment included
subsites other than hilar. The Expert Panel did not include
patients with intrahepatic cholangiocarcinoma within this
recommendation because there is no distinct margin to
target with postoperative radiation for resected intrahepatic
cholangiocarcinoma. The Expert Panel concluded that the
competing risk of distant failure is high for patients with
intrahepatic cholangiocarcinoma, and ablative radiation is
a well-tolerated future option in the unlikely event that there
is an isolated local failure.
Panel members concluded that adjuvant chemoradiation
therapy may be a reasonable option to address the goal of
reducing the risk of local recurrence. The Expert Panel
recommends a shared decision-making approach con-
sidering the limited evidence base and including a dis-
cussion with the patient and relevant caregivers of the risks
of harm and potential for beneﬁt associated with adjuvant
therapy. Further discussion of the consensus-based ra-
tionale for adjuvant therapy within this population is in-
cluded in the Discussion.
DISCUSSION
Until recently, the evidence base for the treatment of
resected biliary tract cancer consisted of mostly smaller
retrospective studies with data combined for intrahepatic
and extrahepatic cholangiocarcinoma and gallbladder
cancer. Previous systematic reviews of retrospective stud-
ies have suggested a beneﬁt of adjuvant therapy for pa-
tients with biliary tract cancer,38 a beneﬁt of adjuvant
radiation for extrahepatic cholangiocarcinoma,39 and an
effect of adjuvant therapy in patients with biliary tract
cancer with positive surgical margins and/or nodal in-
volvement,8 with the caveat that randomized controlled
trials are needed to conﬁrm these exploratory results. This
clinical practice guideline incorporates recently published
data from prospective trials in biliary tract cancer and in-
cludes a review of retrospective studies for a subset of
patients who are at higher risk for microscopically positive
surgical margins.
Results from the BILCAP phase III randomized controlled
trial of adjuvant capecitabine therapy in patients with biliary
tract cancer were recently presented. This article is in press
with Lancet Oncology. and showed a positive effect of
adjuvant therapy on OS compared with observation (51.1 v
36.4months, respectively) in adjusted ITT and per-protocol
analyses, as well as a signiﬁcant difference in RFS, while
ﬁnding no signiﬁcant difference in OS in an unadjusted ITT
analysis. Based on these ﬁndings, the Expert Panel rec-
ommends adjuvant therapy with capecitabine for a period
of 6 months. The Expert Panel noted that the dose of
capecitabine (1,250mg/m2 twice a day) may differ from the
dose that is commonly given at some institutions in the
United States and other locations outside of Europe. To
allow for this practice variation, a qualifying statement that
the recommended dose of capecitabine may be de-
termined by institutional and regional practices was
TABLE 3. Outcomes for the SWOG0809 Phase II Trial of CRT
Study and Year
Interventions
Comparisons No. of Patients DFS OS
Pattern of
First Relapse
Ben-Josef et al,13 2015 CRT (no comparison group) 79 2-year DFS: 54%
(95% CI, 40% to
66%)
2-year OS:
65% (95% CI, 53% to
74%) (exceeded
prespeciﬁed point
estimate threshold for
success of 45%)
R0: 67% (95% CI, 52%
to 78%)
R1: 60% (95% CI, 38%
to 76%) (exceeded
prespeciﬁed point
estimate thresholds
of 65% and 45%,
respectively)
Local: distal, 8%; hilar,
8%; gallbladder, 0%
Distant: distal, 29%;
hilar, 8%; gallbladder,
44%
Local and distant: distal,
13%; hilar, 15%;
gallbladder, 8%
Abbreviations: CRT, chemoradiotherapy; DFS, disease-free survival; OS, overall survival; R0, negative surgical margins14; R1, positive microscopic
margins.14
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included. This is a moderate-strength recommendation,
due to characteristics of the evidence base, such as the
inclusion of only one randomized trial, inconsistency of the
results between per-protocol and ITT analyses, and
questions of generalizability to Asian populations.40 None-
theless, based on the results of BILCAP, there is general
agreement that this option should be offered to patients and
that current and future randomized controlled trials should
use capecitabine as the comparison arm. In response to this
consensus, the ongoing ACTICCA-1 (Adjuvant Chemother-
apyWith Gemcitabine and Cisplatin Compared to Standard of
Care After Curative Intent Resection of Biliary Tract Cancer)
randomized controlled trial has changed its control arm from
surveillance to capecitabine.40
No signiﬁcant difference was detected in RFS or OS be-
tween the treatment and observation arms in other recently
completed phase III randomized controlled trials of adju-
vant gemcitabine (Ebata et al21) or gemcitabine and oxa-
liplatin (PRODIGE 1222). It is difﬁcult to accrue patients with
this uncommon diagnosis to randomized controlled trials,
and in both negative trials, low event rates and/or small
samples likely contributed to inadequate power to detect a
difference between treatment and control groups, but no
trend was observed in terms of OS beneﬁt in either study.
The Expert Panel speciﬁed a review of studies of hilar
cholangiocarcinoma in the guideline protocol because of
the higher risk of R1 resection within this patient subgroup.
A systematic search resulted in 16 studies that met the
inclusion criteria, and data were extracted according to
resection margin status when that information was avail-
able. Due to limitations of the evidence base, including
small sample sizes and inconsistency of results, the Expert
Panel’s recommendation for adjuvant therapy for patients
with positive microscopic resection margins was largely
based on the informal consensus of the Expert Panel, as
well as data showing positive outcomes associated with
adjuvant therapy in the higher risk population of patients
with R1 resections across disease subsites, including
gallbladder and distal extrahepatic cholangiocarcinoma.
Although patients with hilar tumors were the focus of the
literature search and would compose the majority of pa-
tients affected by Recommendation 2, the Expert Panel
chose to provide guidance for treatment of all patients with
extrahepatic and gallbladder tumors with R1 resection
because the effectiveness of adjuvant therapy would not be
expected to differ by disease site.
Due to the current low quality of the evidence base, a
shared decision-making approach was emphasized, in-
cluding a patient-clinician discussion of the risks of harm
and potential for beneﬁt associated with treatment.
Further consensus-based recommendations for higher risk
patients based on combination of lymph node positivity and
margin status were considered to be outside the scope of
this guideline. However, the Expert Panel noted a rationale
for capecitabine chemotherapy in lymph node–positive
patients with R0 resections to control distant spread of
disease, while patients with positive lymph nodes and
positive surgical margins could beneﬁt from capecitabine
and chemoradiation therapy to control both local and
distant recurrence. In addition, the Expert Panel consid-
ered that the order of implementation of Recommendations
1 and 2 would depend on the characteristics of individual
patients and institutional practices.
The recommendations contained within this guideline in-
corporate the most recent evidence for treatment of biliary
tract cancer, including evidence from the BILCAP study12
of capecitabine monotherapy, the ﬁrst positive phase III
randomized controlled trial in resected biliary tract cancer.
In addition, important phase III data are provided in the
Ebata et al21 and PRODIGE 1222 randomized controlled
trials and the SWOG0809 phase II trial,13 which surpassed
its predetermined threshold for efﬁcacy and demonstrates
the feasibility of conducting a national trial in this patient
population. This guideline also provides an evidence- and
consensus-based recommendation for patients with mi-
croscopically positive surgical margins. The results of the
ongoing ACTICCA-1 randomized controlled trial40 of
capecitabine compared with cisplatin plus gemcitabine are
awaited to further inform evidence-based recommenda-
tions for biliary tract cancer. Results of the Japan Clinical
Oncology Group 1202 study comparing adjuvant S-1
to surveillance in resected biliary tract cancer might
also add information about the role of ﬂuoropyrimidines in
this setting.41 There is also a need for future research
that focuses on high-risk patient subgroups and reports
results for speciﬁc biliary tract subsites and/or speciﬁc
molecular alterations. The Expert Panel members will
continue to assess the currency of these recommendations
and consider the need to update this guideline on an
annual basis.
PATIENT AND CLINICIAN COMMUNICATION
For recommendations and strategies to optimize patient-
clinician communication, see “Patient-Clinician Commu-
nication: American Society of Clinical Oncology Consensus
Guideline.”42
HEALTH DISPARITIES
Although ASCO clinical practice guidelines represent ex-
pert recommendations on the best practices in disease
management to provide the highest level of cancer care, it is
important to note that many patients have limited access to
medical care. Racial and ethnic disparities in health care
contribute signiﬁcantly to this problem in the United States.
Patients with cancer who are members of racial or ethnic
minorities suffer disproportionately from comorbidities,
experience more substantial obstacles to receiving care,
are more likely to be uninsured, and are at greater risk of
receiving care of poor quality than other Americans.43-46
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Many other patients lack access to care because of their
geographic location and distance from appropriate treat-
ment facilities. Awareness of these disparities in access to
care should be considered in the context of this clinical
practice guideline, and health care providers should strive
to deliver the highest level of cancer care to these vul-
nerable populations.
MULTIPLE CHRONIC CONDITIONS
Creating evidence-based recommendations to inform
treatment of patients with additional chronic conditions, a
situation in which the patient may have two or more such
conditions—referred to as multiple chronic conditions
(MCCs)—is challenging. Patients with MCCs are a complex
and heterogeneous population, making it difﬁcult to ac-
count for all of the possible permutations to develop speciﬁc
recommendations for care. In addition, the best available
evidence for treating index conditions, such as cancer, is
often from clinical trials whose study selection criteria may
exclude these patients to avoid potential interaction effects
or confounding of results associated with MCC. As a result,
the reliability of outcome data from these studies may be
limited, thereby creating constraints for expert groups to
make recommendations for care in this heterogeneous
patient population.
Because many patients to whom guideline recommenda-
tions apply present with MCCs, any treatment plan needs to
take into account the complexity and uncertainty created
by the presence of MCCs, highlighting the importance of
shared decision making regarding guideline use and
implementation. Therefore, in consideration of recom-
mended care for the target index condition, clinicians
should review all other chronic conditions present in the
patient and take those conditions into account when for-
mulating the treatment and follow-up plan.
In light of these considerations, practice guidelines should
provide information on how to apply the recommendations
for patients with MCCs, perhaps as a qualifying statement
for recommended care. This may mean that some or all of
the recommended care options are modiﬁed or not applied,
as determined by best practice in consideration of any
MCCs.
COST IMPLICATIONS
Increasingly, individuals with cancer are required to pay a
larger proportion of their treatment costs through de-
ductibles and coinsurance.47,48 Higher patient out-of-
pocket costs have been shown to be a barrier to initiating
and adhering to recommended cancer treatments.49,50
Discussion of cost can be an important part of shared
decision making.51 Clinicians should discuss with patients
the use of less expensive alternatives when it is practical
and feasible for treatment of the patient’s disease and there
are two or more treatment options that are comparable in
terms of beneﬁts and harms.51
Patient out-of-pocket costs may vary depending on in-
surance coverage. Coverage may originate in the medical or
pharmacy beneﬁt, which may have different cost-sharing
arrangements. Patients should be aware that different
products may be preferred or covered by their particular
insurance plan. Even with the same insurance plan, the
price may vary between different pharmacies. When dis-
cussing ﬁnancial issues and concerns, patients should be
made aware of any ﬁnancial counseling services available to
address this complex and heterogeneous landscape.51
As part of the guideline development process, ASCO may
opt to search the literature for published cost-
effectiveness analyses that might inform the relative
value of available treatment options. Excluded from
consideration are cost-effectiveness analyses that lack
contemporary cost data, include agents that are not
currently available in either the United States or Canada,
and/or are industry sponsored. No cost-effectiveness
analyses were identiﬁed to inform the topic.
OPEN COMMENT
The draft recommendations were released to the public for
open comment from August 31, 2018, through September
14, 2018. Response categories of “Agree as written,” “Agree
with suggested modiﬁcations,” and “Disagree. See com-
ments” were captured for every proposed recommendation
with three written comments received. Two of the three
respondents either agreed or agreed with slight modiﬁca-
tions to the recommendations, and one respondent dis-
agreed with Recommendation 1. Expert Panel members
reviewed comments from all sources and determined
whether to maintain original draft recommendations, revise
with minor changes, or consider major recommendation
revisions. All changes were incorporated before Clinical
Practice Guidelines Committee review and approval.
GUIDELINE IMPLEMENTATION
ASCO guidelines are developed for implementation across
health settings. Barriers to implementation include the
need to increase awareness of the guideline recommen-
dations among front-line practitioners and survivors of
cancer and caregivers and also to provide adequate ser-
vices in the face of limited resources. The guideline Bottom
Line box was designed to facilitate implementation of
recommendations. This guideline will be distributed widely
through the ASCO Practice Guideline Implementation
Network. ASCO guidelines are posted on the ASCOWeb site
and most often published in Journal of Clinical Oncology
and Journal of Oncology Practice.
ASCO believes that cancer clinical trials are vital to
inform medical decisions and improve cancer care
Journal of Clinical Oncology 1025
Adjuvant Therapy for Resected Biliary Tract Cancer
 Copyright © 2019 American Society of Clinical Oncology. All rights reserved.
and that all patients should have the opportunity to
participate.
ADDITIONAL RESOURCES
More information, including a Data Supplement with addi-
tional evidence tables, slide sets, and clinical tools and re-
sources, is available at www.asco.org/gastrointestinal-cancer-
guidelines. TheMethodology Manual (available at www.asco.
org/guideline-methodology) provides additional information
about the methods used to develop this guideline. Patient
information is available at www.cancer.net.
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